Human Growth Hormone-Releasing Hormone (hGH-RH; hGRF) Treatment of Four Patients with GH Deficiency

• Published in: Endocrinologia Japonica Vol. 35; no. 5; pp. 775 - 781
• Main Authors: TAKANO, KAZUE, HIZUKA, NAOMI, ASAKAWA, KUMIKO, CHIHARA, KAZUO, SANAYAMA, KAZUNORI, SHIZUME, KAZUO
• Format: Journal Article
• Language: English
• Published: Tokyo The Japan Endocrine Society 1988; Japan Endocrine Society
• Subjects: Adolescent; Biological and medical sciences; Child; Female; Growth Disorders - drug therapy; Growth Disorders - metabolism; Growth Hormone - deficiency; Growth Hormone-Releasing Hormone - administration & dosage; Growth Hormone-Releasing Hormone - therapeutic use; Hormones. Endocrine system; Humans; Injections, Intravenous; Male; Medical sciences; Pharmacology. Drug treatments
• ISSN: 0013-7219; 2185-6370
• DOI: 10.1507/endocrj1954.35.775

Four patients with GH deficiency aged 6-14 years old were treated with hGRF for 6months. Before the treatment maximal plasma GH responses to 50μg iv hGRF administration were 48.6, 12.1, 24.3 and 13.0ng/ml, respectively. Human GRF was administered at a dosage of 50-100μg twice a day subcutaneously. In two patients, the growth rate was increased from 2.4 and 2.0cm/year to 8.2 and 9.8cm/year, respectively. In the other two patients, the growth rate did not change with hGRF treatment. Plasma somatomedin C levels increased in one patient but did not change in the other three. Antibody to hGRF was observed in two patients during the treatment, but the presence of antibody did not affect the growth rate.